Considerations for Advanced Heart Failure Consultation in Individuals With Fontan Circulation: Recommendations From ACTION.


Journal

Circulation. Heart failure
ISSN: 1941-3297
Titre abrégé: Circ Heart Fail
Pays: United States
ID NLM: 101479941

Informations de publication

Date de publication:
02 2023
Historique:
pubmed: 15 2 2023
medline: 25 2 2023
entrez: 14 2 2023
Statut: ppublish

Résumé

Individuals with Fontan circulation are at risk of late mortality from both cardiac and noncardiac causes. Despite the known risk of mortality, referral indications for advanced heart failure care vary between centers, and many individuals die from Fontan circulation-related complications either after late consideration for advanced heart failure therapies or having never seen a heart failure specialist. There is a critical need for guidelines to direct appropriately timed referral for advanced heart failure consultation. The Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Fontan Committee has developed recommended thresholds for advanced heart failure referral to guide primary cardiologists. These recommendations are divided into 4 categories of clinical Fontan circulatory dysfunction including (1) cardiac/systemic ventricular dysfunction, (2) Fontan pathway dysfunction, (3) lymphatic dysfunction, and (4) extracardiac dysfunction.

Identifiants

pubmed: 36786204
doi: 10.1161/CIRCHEARTFAILURE.122.010123
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e010123

Auteurs

Adam M Lubert (AM)

Cincinnati Children's Hospital Heart Institute, Department of Pediatrics, University of Cincinnati College of Medicine, OH (A.M.L., A.L., D.L.S.M., L.S.).

Ari Cedars (A)

Johns Hopkins University, Baltimore, MD (A.C.).

Christopher S Almond (CS)

Stanford University School of Medicine (Pediatrics) and Stanford Children's Health, Palo Alto, CA (C.S.A., D.N.R.).

Shahnawaz Amdani (S)

Cleveland Clinic Children's, OH (S.A.).

Jennifer Conway (J)

Stollery Children's Hospital, Edmonton, Alberta, Canada (J.C.).

Joshua M Friedland-Little (JM)

Seattle Children's Hospital, WA (J.M.F.-L.).

Robert J Gajarski (RJ)

Nationwide Children's Hospital, Columbus, OH (R.J.G.).

Steven J Kindel (SJ)

Children's Hospital of Wisconsin and Herma Heart Institute, Medical College of Wisconsin, Milwaukee (S.J.K.).

Angela Lorts (A)

Cincinnati Children's Hospital Heart Institute, Department of Pediatrics, University of Cincinnati College of Medicine, OH (A.M.L., A.L., D.L.S.M., L.S.).

David L S Morales (DLS)

Cincinnati Children's Hospital Heart Institute, Department of Pediatrics, University of Cincinnati College of Medicine, OH (A.M.L., A.L., D.L.S.M., L.S.).

Matthew J O'Connor (MJ)

Children's Hospital of Philadelphia, PA (M.J.O.).

David M Peng (DM)

Congenital Heart Center, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor (D.M.P., K.R.S.).

David N Rosenthal (DN)

Stanford University School of Medicine (Pediatrics) and Stanford Children's Health, Palo Alto, CA (C.S.A., D.N.R.).

Lauren Smyth (L)

Cincinnati Children's Hospital Heart Institute, Department of Pediatrics, University of Cincinnati College of Medicine, OH (A.M.L., A.L., D.L.S.M., L.S.).

David L Sutcliffe (DL)

Children's Mercy Hospital, Kansas City, MO (D.L.S.).

Kurt R Schumacher (KR)

Congenital Heart Center, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor (D.M.P., K.R.S.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH